BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

The Japanese drugmaker is best known for antibody-drug conjugates (ADCs), having secured deals with AstraZeneca and Merck & Co. and spawned the blockbuster Enhertu. But Daiichi has a long-standing ...

第一三共凭借其ADC（抗体偶联药物）技术平台及核心产品德曲妥珠单抗（ENHERTU）的商业化成功，成为全球ADC领域的标杆。截至2025年初，ENHERTU已在 ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

The drug induced a response—defined as ... AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer AstraZeneca and Daiichi Sankyo’s Enhertu ...

While the selection of linkers for PDCs offers greater flexibility compared to ADCs, the PDCdb indicates that only 140 distinct linkers are currently employed in the formulation of PDC drugs (Sun et ...